Astrazeneca Plc Class Action Lawsuit - AZN

Company
Astrazeneca Plc (NYSE: AZN)
Lead Plaintiff Deadline
March 29, 2021 (Expired)
Class Period
May 21, 2020 - November 20, 2020

Expired

Lead Plaintiff Deadline

Mar 29, 2021

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

(a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca’s clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

Eligibility

In order to be eligible to join the AZN class action lawsuit, you must have incurred a loss on shares of Astrazeneca purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Astrazeneca during the relevant time frame or pursuant to the relevant offering(s), you have until March 29, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

TOP